Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells
Marija Mojić(Northwell Health), Ferdinando Nicoletti(University of Catania), Salvatore Travali(University of Catania), Marco Donia(University of Copenhagen), James A. McCubrey(East Carolina University), Katia Mangano(University of Catania), Djordje Miljković(University of Belgrade), Mai-Britt Zocca(Northwell Health), Stanislava Stošić‐Grujičić(Institute for Biological Research “Siniša Stanković”), Yousef Al‐Abed(Feinstein Institute for Medical Research), Danijela Maksimović‐Ivanić(Institute for Biological Research “Siniša Stanković”), Marija Stanković(University of Belgrade), Sanja Mijatović(University of Belgrade), Paolo Fagone(University of Catania)
Cited by 29
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495